Evolus, Inc. reaffirmed revenue guidance for full year 2022. For the period, based on its year-to-date performance and confidence in a resilient and fundamentally strong aesthetic neurotoxin market, the company continues to believe it can achieve the upper end of its full-year sales guidance range of $143 million to $150 million. This assumes a minimal contribution from international markets.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.93 USD | +2.62% | +3.36% | +22.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.79% | 810M | |
+40.73% | 739B | |
+31.00% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.89% | 240B | |
+9.33% | 210B | |
-5.19% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022